Author

O. I. Olopade

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Biochemistry· 1 Cancer Biology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Organism:human· 2 Assay:bulk RNA-seq· 1 Research Focus:cell signaling & trafficking· 1 Assay:clinical cohort / trial· 1 Approach:deep learning· 1 Research Focus:drug response / drug discovery· 1 Approach:experimental assay· 1 Research Focus:gene regulatory network inference· 1

Frequent Co-Authors

A. Srisuwananukorn· 1 shared A. T. Pearson· 1 shared A. Woodard· 1 shared C. He· 1 shared C. M. Perou· 1 shared C. Ye· 1 shared D. Huo· 1 shared F. M. Howard· 1 shared

Activity by Year

2022-2023 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 29 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

1 shared paperCancer Biology

A. Srisuwananukorn

Mutual co-authors in cluster

Author profile →

2 papers

Recent·Most cited

PTPN2 copper-sensing rapidly relays copper level fluctuations into EGFR/CREB activation and associated CTR1 transcriptional repression

M. O. Ross, Y. Xie, R. C. Owyang, C. Ye, O. N. P. Zbihley, R. Lyu, T. Wu, P. Wang, O. Karginova, O. I. Olopade, M. Zhao, C. He

The paper identifies PTPN2 as a copper sensor that modulates EGFR/CREB signaling and CTR1 transcriptional repression in response to copper level changes.

bioRxiv · Aug 29, 2023 · PreprintBiochemistry

Multimodal Prediction of Breast Cancer Recurrence Assays and Risk of Recurrence

F. M. Howard, J. Dolezal, S. Kochanny, G. Khramtsova, J. Vickery, A. Srisuwananukorn, A. Woodard, N. Chen, R. Nanda, C. M. Perou, O. I. Olopade, D. Huo, A. T. Pearson

This paper develops a deep learning model that predicts breast cancer recurrence using digital histology and clinical factors, outperforming a clinical nomogram and identifying patients who may avoid genomic testing.

bioRxiv · Jul 7, 2022 · PreprintCancer Biology